Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 376

1.

Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.

Lucas TM, Janaka SK, Stephens EB, Johnson MC.

PLoS One. 2012;7(12):e51741. doi: 10.1371/journal.pone.0051741. Epub 2012 Dec 19.

2.

Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu.

Lucas TM, Lyddon TD, Cannon PM, Johnson MC.

J Virol. 2010 Mar;84(6):2666-74. doi: 10.1128/JVI.01562-09. Epub 2009 Dec 30.

3.

Sequences in gibbon ape leukemia virus envelope that confer sensitivity to HIV-1 accessory protein Vpu.

Janaka SK, Lucas TM, Johnson MC.

J Virol. 2011 Nov;85(22):11945-54. doi: 10.1128/JVI.05171-11. Epub 2011 Sep 14. Erratum in: J Virol. 2013 Jun;87(12):7198.

4.
5.

Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.

Christodoulopoulos I, Droniou-Bonzom ME, Oldenburg JE, Cannon PM.

Retrovirology. 2010 Jan 26;7:4. doi: 10.1186/1742-4690-7-4.

6.

Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.

Nikovics K, Dazza MC, Ekwalanga M, Mammano F, Clavel F, Saragosti S.

PLoS One. 2012;7(4):e35411. doi: 10.1371/journal.pone.0035411. Epub 2012 Apr 17.

7.

HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.

Pujol FM, Laketa V, Schmidt F, Mukenhirn M, Müller B, Boulant S, Grimm D, Keppler OT, Fackler OT.

J Virol. 2016 Jul 11;90(15):6709-23. doi: 10.1128/JVI.00504-16. Print 2016 Aug 1.

8.

β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.

Tervo HM, Homann S, Ambiel I, Fritz JV, Fackler OT, Keppler OT.

Retrovirology. 2011 Feb 10;8:9. doi: 10.1186/1742-4690-8-9.

9.

Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.

Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM.

J Virol. 2010 Jul;84(14):7243-55. doi: 10.1128/JVI.02636-09. Epub 2010 May 5.

10.

The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.

Kluge SF, Sauter D, Vogl M, Peeters M, Li Y, Bibollet-Ruche F, Hahn BH, Kirchhoff F.

Retrovirology. 2013 Mar 20;10:32. doi: 10.1186/1742-4690-10-32.

11.

Vpu binds directly to tetherin and displaces it from nascent virions.

McNatt MW, Zang T, Bieniasz PD.

PLoS Pathog. 2013;9(4):e1003299. doi: 10.1371/journal.ppat.1003299. Epub 2013 Apr 25.

13.

Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Vigan R, Neil SJ.

J Virol. 2010 Dec;84(24):12958-70. doi: 10.1128/JVI.01699-10. Epub 2010 Oct 6.

14.

Overexpression of inactive tetherin delGPI mutant inhibits HIV-1 Vpu-mediated antagonism of endogenous tetherin.

Lv M, Wang J, Zhu Y, Wang X, Zuo T, Liu D, Zhang J, Wu J, Zhang H, Kong W, Yu X.

FEBS Lett. 2013 Jan 4;587(1):37-43. doi: 10.1016/j.febslet.2012.11.022. Epub 2012 Nov 28.

15.

HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.

Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V.

PLoS Pathog. 2009 Sep;5(9):e1000574. doi: 10.1371/journal.ppat.1000574. Epub 2009 Sep 4.

16.

Lack of adaptation to human tetherin in HIV-1 group O and P.

Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM.

Retrovirology. 2011 Sep 28;8:78. doi: 10.1186/1742-4690-8-78.

17.

Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT.

PLoS Pathog. 2009 May;5(5):e1000429. doi: 10.1371/journal.ppat.1000429. Epub 2009 May 15.

18.

Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.

Rollason R, Dunstan K, Billcliff PG, Bishop P, Gleeson P, Wise H, Digard P, Banting G.

PLoS One. 2013 Sep 24;8(9):e75680. doi: 10.1371/journal.pone.0075680. eCollection 2013.

19.

Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.

Lv M, Wang J, Wang X, Zuo T, Zhu Y, Kong W, Yu X.

PLoS One. 2011;6(6):e20890. doi: 10.1371/journal.pone.0020890. Epub 2011 Jun 2.

20.

HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.

Sauter D, Hué S, Petit SJ, Plantier JC, Towers GJ, Kirchhoff F, Gupta RK.

Retrovirology. 2011 Dec 15;8:103. doi: 10.1186/1742-4690-8-103.

Supplemental Content

Support Center